Covid biotech’s stock jumps after positive early PhIII monoclonal antibody data reveal

In­vivyd on Mon­day re­port­ed pos­i­tive ear­ly Phase III da­ta for its mon­o­clon­al an­ti­body de­signed to pre­vent symp­to­matic Covid-19 among im­muno­com­pro­mised in­di­vid­u­als, trig­ger­ing the biotech’s stock $IVVD to jump by as much as 150%.

In the Phase III CANOPY study’s co­pri­ma­ry end­point, the mon­o­clon­al an­ti­body, dubbed VYD222, de­liv­ered high titer lev­els of serum virus neu­tral­iz­ing an­ti­bod­ies (sV­NA) against the SARS-CoV-2 vari­ant XBB.1.5 among sig­nif­i­cant­ly im­muno­com­pro­mised in­di­vid­u­als, much like what was re­port­ed in an ear­li­er study with healthy par­tic­i­pants, as per a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.